PRTO Proteon Therapeutics Inc

Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company management will present a corporate overview at the following upcoming investor conferences:

• The 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, on September 5, 2018 in New York, NY; and 
• The Baird 2018 Global Healthcare Conference on September 5, 2018 in New York, NY.

About Proteon TherapeuticsProteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon's lead product candidate, vonapanitase, is an investigational drug intended to improve hemodialysis vascular access outcomes. Proteon has completed enrollment in PATENCY-2, a Phase 3 clinical trial evaluating vonapanitase in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis. Proteon is also evaluating vonapanitase in a Phase 1 clinical trial in patients with peripheral artery disease (PAD). For more information, please visit www.proteontx.com.

Investor ContactGeorge Eldridge, Proteon Therapeutics, Senior Vice President and Chief Financial Officer781-890-0102geldridge@proteontherapeutics.com

Media ContactAnn Stanesa, Ten Bridge Communications617-230-0347proteon@tenbridgecommunications.com